Trial Profile
A Phase I/II Trial of CDX-1401 (a Vaccine Consisting of a Human Monoclonal Antibody Specific for DEC-205, Fused to Full-length Tumor Antigen NY-ESO-1) in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Poly ICLC (Primary) ; Rasdegafusp-alfa (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 05 Dec 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 Jul 2016 New trial record
- 21 Jul 2016 Planned initiation date changed from 1 Jul 2016 to 1 Dec 2016.